Effect of supplementation in treatment of patients with diabetic nephropathy

Phase 3

• Conditions: Diabetic nephropathy.; Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+); N08.3

• Registration Number: IRCT201611155623N93
• Lead Sponsor: Vice chancellor for research, Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with diabetic nephropathy
Aged 40 to 80 years

Exclusion Criteria

Consumption of any nutritional supplements within 3 months
History of active infection within 3 months
History of hospital admission within 3 months
Malignancy and/or liver cirrhosis
Subjects with uncontrolled diabetes
Pregnant women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expressed levels of PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

Secondary Outcome Measures

Name	Time	Method
Expressed levels of Lp(a) gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-8 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of ox-LDL gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.